Ferroptosis-centered Disease Response Information
General Information of the Disease (ID: DIS00064)
| Name |
Hereditary haemochromatosis
|
||||
|---|---|---|---|---|---|
| ICD |
ICD-11: 5C64
|
||||
Full List of Target(s) of This Ferroptosis-centered Disease
Heme oxygenase 1 (HMOX1)
| In total 1 item(s) under this target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | ||||
| Target for Ferroptosis | Driver/Suppressor | ||||
| Responsed Disease | Hereditary haemochromatosis [ICD-11: 5C64] | ||||
| Responsed Regulator | Fibroblast growth factor 21 (FGF21) | Suppressor | |||
| Pathway Response | Fatty acid metabolism | hsa01212 | |||
| Ferroptosis | hsa04216 | ||||
| Cell Process | Cell ferroptosis | ||||
| In Vitro Model | mPHs (Mouse primary hepatocytes) | ||||
| In Vivo Model |
In the adenovirus-mediated FGF21 over-expression mouse model, 12-week-old C57BL/6J male mice were divided into four groups: (1) EGFP vector overexpression + PBS injection group (n = 10), (2) EGFP vector overexpression + iron dextran injection group (n = 10), (3) FGF21-EGFP overexpression + PBS injection group (n = 10) and (4) FGF21-EGFP overexpression + iron dextran injection group (n = 10). The mice were administered PBS and iron dextran by intraperitoneal injection for 7 days.
Click to Show/Hide
|
||||
| Response regulation | FGF21 could protect hepatocytes from developing iron overload-induced ferroptosis by stimulating HO-1 ubiquitination and subsequent degradation. The FGF21HO-1 pathway could be targeted for treating iron overload-induced ferroptosis-related diseases, particularly hereditary haemochromatosis (HH). | ||||